Impaired estimated functional capacity using DASI as proxy (defined by age-normative metabolic equivalent of tasks \[METs\])
History of COVID-19 (stratified by hospital admission)
Currently symptomatic with fatigue, dyspnoea or chest pain symptoms
Medicare eligibility
Ability and willingness to provide written informed consent to participate in the study. The patient will need to be able to communicate fluently with the investigator. The investigator will need to be satisfied that the patient understands the study by having them explain the study plan back to the investigator.
You may not be if
Unable to provide written informed consent to participate in this study
Participating in another research trial where randomized treatment would be unacceptable
Mobility impairment that would impact participants' ability to perform exercise
History of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Known valvular stenosis or regurgitation of \>moderate severity, history of previous heart failure (baseline New York Heart Association \[NYHA\] \>2)
Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
Clareo Health | PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID
